Jones Trading Reiterates Buy Rating on Alterity Therapeutics
On June 30, 2026, Jones Trading reiterated its buy rating for Alterity Therapeutics with a $16 price target, a 197.95% upside from the current price.
Key Points
- Jones Trading reiterated a buy rating on Alterity Therapeutics (NasdaqCM:ATHE) with a $16 target on June 30, 2026.
- Jones Trading's $16 price target implies 197.95% upside from Alterity Therapeutics Limited's ($ATHE) current $5.37 share price.
- Alterity Therapeutics traded near $4.89 on Tuesday, with a market cap of about $87.4 million and a 52-week range of $2.66 to $7.00.
- Insiders Julian Michael Babarczy and Lawrence Bernard Gozlan bought 2 million and 1 million shares respectively on June 15, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Jones Trading reiterated its buy rating for Alterity Therapeutics Limited (NasdaqCM:ATHE), setting a price target of $16. The analyst, Debanjana Chatterjee, maintained her positive outlook on the biotechnology company.
Jones Trading vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Alterity Therapeutics Limited Stock Up 19.1%
Shares of Alterity Therapeutics traded near $4.89 on Tuesday. The company, which is involved in developing treatments for Parkinsonian and neurodegenerative disorders, has a market cap of approximately $87.4 million. It has a 52-week low of $2.66 and a high of $7.00. The stock's 50-day moving average is $4.45, and the 200-day moving average is $3.89. Despite having a negative forward P/E ratio of -4.08 due to lack of profitability, the company boasts a strong current ratio of 21.98 and a quick ratio of 21.68, indicating solid liquidity.
$ATHE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Alterity Therapeutics Limited
Insider activity at Alterity Therapeutics saw significant buying on June 15, 2026. Julian Michael Babarczy acquired 2 million shares, while Lawrence Bernard Gozlan purchased 1 million shares. These transactions did not involve any planned trading arrangements.
Analysts Set New Price Targets
On June 30, 2026, Jones Trading reiterated its buy rating for Alterity Therapeutics, setting a price target of $16. Previously, on June 16, 2026, Ladenburg Thalmann assumed coverage with a buy rating and a $10 target. Maxim Group maintained its buy rating with a $12 target on January 30, 2025. The consensus among analysts is a strong buy, with a mean target price of $11.
About Alterity Therapeutics
Alterity Therapeutics Limited, headquartered in Melbourne, Australia, focuses on the research and development of treatments for neurodegenerative diseases, including Parkinson's disease and Multiple System Atrophy. Led by CEO Dr. David A. Stamler, the company is advancing its lead drug candidate, ATH434, through Phase II clinical trials. With a small team of just nine employees, Alterity is also working on developing additional compounds to address neurological conditions.
Bottom Line
Jones Trading's reiteration of a buy rating for Alterity Therapeutics highlights ongoing confidence in the company's future prospects. Shares were trading near $4.89, reflecting the market's current valuation. Investors often follow such analyst updates to gauge potential stock performance. As always, it's important to remember that these ratings reflect past analyses and may not indicate current positions.
Get Alterity Therapeutics Limited alerts
New 13F filings, insider trades, and analyst moves on $ATHE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.